SPPI

Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction

Retrieved on: 
Tuesday, August 1, 2023
ASRT, American Red Cross, HIV, Lab, Physical Sciences in Oncology Network, FACP, Spectrum Pharmaceuticals, Cancer, Community Oncology Alliance, Brooklyn Hospital Center, IP, Martin PBM Mariner, Acquisition, Medical director, Patient, Physician, Injection, AIDS Care, The Ride to Conquer Cancer, Greater New York, Newsday, Long Island Association, Red Door (venue), SPPI, EPS, Adjustment, Health, Coronavirus Scientific Advisory Board, COA, Hospital, Nursing, Pharmaceutical industry, MD, Spectrum

LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology.

Key Points: 
  • LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology.
  • Assertio intends to provide updated guidance for the combined business as part of its second quarter results call on August 3.
  • He also serves on the board of directors of Annexus Health, Spectrum Pharmaceuticals, OneOncology, and the American Red Cross of Greater New York.
  • Dr. Vacirca also received the Theodore Roosevelt Award for outstanding dedication to patient care and was named Newsday's Top Doctor.

Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals

Retrieved on: 
Thursday, July 27, 2023
ASRT, SPPI, Spectrum Pharmaceuticals, CVR, Patient, Spectrum, Fine chemical, Cryptocurrency, Pharmaceutical industry, Assertio Therapeutics

LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and contingent value rights (CVR) transaction.

Key Points: 
  • LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and contingent value rights (CVR) transaction.
  • “We are pleased to announce the positive voting results of each meeting and look forward to closing the transaction in the coming days,” said Dan Peisert, President and Chief Executive Officer of Assertio.
  • “We believe this transaction provides extensive new growth opportunities and will be accretive to our stockholders in 2024.
  • We plan to provide updated guidance on our second quarter results call, scheduled for August 3.”

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.

Retrieved on: 
Thursday, July 20, 2023
Technology, Clinical Trials, Health Technology, Software, Stem Cells, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Agreement, Plan, Institutional Shareholder Services, Tripura Merger Agreement, Medication, Glass Lewis, SPPI, ISS, Holding company, Spectrum

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”) announced today that the leading independent proxy advisory firms, Institutional Shareholder Services, Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have each recommended that Spectrum stockholders vote “FOR” the proposal to adopt the Agreement and Plan of Merger (“Merger Agreement”, and such proposal, the “Merger Proposal”) at the upcoming special meeting of stockholders (the “Special Meeting”) on July 27, 2023.

Key Points: 
  • Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”) announced today that the leading independent proxy advisory firms, Institutional Shareholder Services, Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have each recommended that Spectrum stockholders vote “FOR” the proposal to adopt the Agreement and Plan of Merger (“Merger Agreement”, and such proposal, the “Merger Proposal”) at the upcoming special meeting of stockholders (the “Special Meeting”) on July 27, 2023.
  • Under the terms of the Merger Agreement, Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio”) would acquire all outstanding shares of Spectrum in an all-stock and contingent value rights (“CVR”) transaction.
  • The upfront consideration represents a premium of 65% and the total potential consideration represents a premium of 94% to Spectrum’s closing price on April 24, 2023.
  • “We urge all stockholders to make sure their shares are represented at the special meeting by voting today.”
    The Spectrum board of directors strongly urges Spectrum stockholders to vote “FOR” all the proposals on the agenda.

SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI

Retrieved on: 
Friday, June 30, 2023
Class Action Lawsuit, Professional Services, Legal, Calendar, SPPI, Spectrum Pharmaceuticals, Assertio Therapeutics, KSF, Sale, Spectrum

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) to Assertio Holdings, Inc. (NasdaqCM: ASRT).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Retrieved on: 
Wednesday, May 17, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Medication, SPPI, Staff, Auction

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Key Points: 
  • Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
  • The Company previously received notification from the Staff on November 1, 2022, that its common stock failed to maintain a minimum bid price of $1.00 or more over the previous 30 consecutive business days, as required by the Nasdaq Listing Rules.
  • Since then, the Staff has determined that for the 10 consecutive business days from May 2 to May 15, 2023, the closing bid price of Spectrum’s common stock has been at $1.00 per share or greater.
  • Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.

Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Workforce, CVR, Quarter, Marketing, Continuous operation, Spectrum Pharmaceuticals, Research, Medication, Acquisition, Patient, Injection, Hanmi Pharmaceutical, SPPI, Growth, Assertio Therapeutics, FDA, Spectrum, Pharmaceutical industry, Video game, Cryptocurrency

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update.

Key Points: 
  • Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update.
  • 172 targeted accounts purchased ROLVEDON™ (eflapegrastim-xnst) Injection during the quarter compared to 70 in Q4 2022, an increase of 145%.
  • “Spectrum delivered a strong start to 2023 with outstanding execution in the launch of ROLVEDON.
  • The Company had a total cash, cash equivalents, and marketable securities balance of approximately $56.1 million as of March 31, 2023.

SHAREHOLDER ALERT: Weiss Law Reminds SPPI, NATI, CCFN, and ARST Shareholders About Its Ongoing Investigations

Retrieved on: 
Monday, May 1, 2023
ASRT, Spectrum Pharmaceuticals, Multimedia, NATI, Acquisition, Assertio Therapeutics, OTC, Law, SPPI, National Instruments

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), in connection with its acquisition by Assertio Holdings, Inc. ("Assertio").

Key Points: 
  • Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), in connection with its acquisition by Assertio Holdings, Inc. ("Assertio").
  • Under the merger agreement, SPPI shareholders will receive 0.1783 shares of Assertio common stock for each of their shares, representing implied per-share consideration of $0.98 based upon Assertio's April 28, 2023 closing price of $5.51.
  • Additionally, Spectrum Pharmaceuticals shareholders will receive one Contingent Value Right ("CVR") per Spectrum share entitling them to receive up to an additional $0.20 per share in total.
  • Under the merger agreement, NATI shareholders will receive $60.00 in cash for each share of NATI owned.

Lifshitz Law PLLC Announces Investigations of HOTH, ASRT, SPPI, and CEI

Retrieved on: 
Sunday, April 30, 2023
Telephone, ASRT, PLLC, SPPI, Assertio Therapeutics, CEI, Advertising, Hewlett, Spectrum, Online shopping, Financial adviser

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of ASRT with Spectrum Pharmaceuticals, Inc., whereby Spectrum shareholders will receive a fixed exchange ratio of 0.1783 shares of Assertio for each share of Spectrum owned.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of ASRT with Spectrum Pharmaceuticals, Inc., whereby Spectrum shareholders will receive a fixed exchange ratio of 0.1783 shares of Assertio for each share of Spectrum owned.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CEI with Viking Energy Group Inc.
  • ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

ALERT: The M&A Class Action Firm Continues the Investigation of the Merger – MYBF, RXDX, SPPI, TRTN

Retrieved on: 
Wednesday, April 26, 2023
CVR, Empire, Sale, Acquisition, OTC, Monteverde, SPPI, Assertio Therapeutics, NYSE, Brookfield Infrastructure Partners, Security (finance), Merck

Under the terms of the agreement, MYBF shareholders are expected to receive 0.9259 shares of CCFNB per share they own.

Key Points: 
  • Under the terms of the agreement, MYBF shareholders are expected to receive 0.9259 shares of CCFNB per share they own.
  • Prometheus Biosciences, Inc. (NASDAQ: RXDX ), relating to its proposed sale to Merck and Co.
  • Under the terms of the agreement, RXDX shareholders are expected to receive $200.00 in cash per share they own.
  • Triton International Ltd. (NYSE: TRTN ), relating to its proposed sale to Brookfield Infrastructure Partners, L.P. Click here for more information: https://www.monteverdelaw.com/case/triton-international-ltd .

SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI

Retrieved on: 
Wednesday, April 26, 2023
Class Action Lawsuit, Professional Services, Legal, Calendar, SPPI, Spectrum Pharmaceuticals, Assertio Therapeutics, KSF, Sale, Spectrum

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) to Assertio Holdings, Inc. (NasdaqCM: ASRT).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .